Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Align Technology buy stratec

Start price
Target price
Performance (%)

According to stratec what are the pros and cons of Align Technology for the foreseeable future?

Comments by stratec for this prediction

In the thread Align Technology diskutieren

Published 11.10.18
Prediction Buy
Perf. (%) -4.467%
Target price 455.961

Align Technology is one of the few shining stars ...

Align Technology is one of the few shining stars in the dental sector. The maker of Invisalign invisible braces and iTero Element intraoral scanner was recognized by Goldman Sachs as one of its top stocks for 2019 with an estimated 22% increase in revenue in the coming year. One of the key anticipated drivers of the company's growth is the popularity of the Invisalign product with a key demographic, millennials. From dating apps to job interviews, these consumers are recognizing the importance of a great smile, particularly with the higher resolution of smartphones. And this type of consumer benefit is not limited to the United States. There is a worldwide market for their products.

Align Technology recently signed an agreement with Aspen Dental for both its iTero scanner and Invisalign product. Aspen Dental is not only the largest network of branded dental care practices; it’s also experiencing tremendously rapid growth. Case in point, a new office opens every five days. In short, there’s a huge and growing market for their products.

Although the company’s stock is selling at a premium over $372 and a P/E ratio of over 89, one analyst considers them to be the best buy in dental despite their high valuation.

Published 23.12.19
Prediction Buy
Perf. (%) -4.467%
Target price 355.961

Kursziel geändert auf 355,961

Published 12.05.20
Prediction Buy
Perf. (%) -4.467%
Target price 255.961

Kursziel geändert auf 255,961